A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is
QR Dengue is a serious viral disease presently having no effective antiviral therapy or approved vaccine available. Therefore, design of new drugs against dengue virus replication is a very important challenge. Thiazolidinone derivatives have previously been reported to show antidengue activity in cell culture. Herein, we report the docking study of fused thiazolidinone derivatives against the dengue virus NS2B/NS3 protease. The hydrogen bonding, hydrophobic interactions and Van der Waalsfatcat:e5gdyihhc5dhzkbnz5w3u7i55i